| pubmed-article:8698063 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C0678222 | lld:lifeskim |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C0303611 | lld:lifeskim |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C1337333 | lld:lifeskim |
| pubmed-article:8698063 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:8698063 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8698063 | pubmed:dateCreated | 1996-9-5 | lld:pubmed |
| pubmed-article:8698063 | pubmed:abstractText | An in vitro study was designed to evaluate the uptake of sestamibi (MIBI) in P-glycoprotein (Pgp) and glutathione-associated (GSH) multidrug-resistant (MDR) cell lines. MIBI uptake was studied in various human breast carcinoma cell lines, i.e. in wild-type (MCF7/wt) cells, in adriamycin-resistant (MCF7/adr) cells which express Pgp and in melphalan-resistant (MCF7/mph) cells with increased levels of GSH. The effects of buthiomine sulphoximine (BSO) and verapamil on MIBI uptake were also studied in the MCF7/mph and MCF7/adr cells respectively. The cells were incubated for 1 h with a dose of 0.1 MBq thallium-201 and technetium-99m MIBI. Both MIBI and 201Tl uptakes were higher for MCF7/mph cells than for the other cells studied. The mean MIBI uptake in MCF7/adr cells was significantly lower than that in MCF7/wt cells (1.9%+/-0.5% vs 3. 1%.0.6%; P <0.01). Verapamil treatment increased the MIBI uptake in MCF7/adr cells (to 2.6%.0.3%; P <0.05). Treatment of MCF7/mph cells with BSO resulted in a significant reduction in GSH content (from 243.2+/-81.1 nmol/mg protein to 17.6+/-4.4 nmol/mg protein; P <0. 001). However, MIBI uptake in BSO-treated and untreated MCF7/mph cells was similar (4.43%+/-0.5% and 5.93%+/-1.7%, respectively; P >0. 1). This study suggests that the uptake of MIBI is not diminished by glutathione-associated drug resistance and that MIBI uptake in a tumour sample does not necessarily indicate that a cancer is sensitive to drugs. | lld:pubmed |
| pubmed-article:8698063 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8698063 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8698063 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8698063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8698063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8698063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8698063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8698063 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8698063 | pubmed:month | May | lld:pubmed |
| pubmed-article:8698063 | pubmed:issn | 0340-6997 | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:CollierDD | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:HaywardMM | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:IsitmanA TAT | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:HellmanRR | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:OzkerKK | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:AkanselGG | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:GriffithOO | lld:pubmed |
| pubmed-article:8698063 | pubmed:author | pubmed-author:KabasakalLL | lld:pubmed |
| pubmed-article:8698063 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8698063 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:8698063 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8698063 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8698063 | pubmed:pagination | 568-70 | lld:pubmed |
| pubmed-article:8698063 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:meshHeading | pubmed-meshheading:8698063-... | lld:pubmed |
| pubmed-article:8698063 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8698063 | pubmed:articleTitle | Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. | lld:pubmed |
| pubmed-article:8698063 | pubmed:affiliation | Department of Nuclear Medicine and Biochemistry, Medical College of Wisconsin, Milwaukee, USA. | lld:pubmed |
| pubmed-article:8698063 | pubmed:publicationType | Journal Article | lld:pubmed |
